Paclitaxel tocopheryl-based emulsion - Sorrento Therapeutics

Drug Profile

Paclitaxel tocopheryl-based emulsion - Sorrento Therapeutics

Alternative Names: IG 004; IG-002; paclitaxel TPGS-based emulsion; QW 8184; S 8184; Tocosol paclitaxel

Latest Information Update: 24 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sonus Pharmaceuticals
  • Developer Sorrento Therapeutics
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 23 Nov 2016 Discontinued - Preclinical for Solid tumours (New delivery system) in USA (IV) (Sorrento Therapeutics pipeline, November 2016)
  • 08 Apr 2014 Further analyses of adverse events data from a phase III trial in Breast cancer presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
  • 31 Dec 2013 Preclinical trials in Solid tumours (TPGS-based nanoparticle emulsion) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top